AusCann share price jumps 10% on release of low-dose capsules

The Auscann Group Holdings Ltd (ASX: AC8) share price has leaped 10% today following the release of its low-dose cannabinoid capsules.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Auscann Group Holdings Ltd (ASX: AC8) share price has leaped 10% today following the release of its low-dose cannabinoid capsules.

Shares in AusCann are currently trading at 29.7 cents, up from 26 cents at yesterday's close and a low of 17 cents in December.

The medicinal cannabis pharmaceutical company today announced that it has completed the manufacturing, testing and release of low-dose cannabinoid-based capsules in a commercial batch. 

Customised cannabinoid dosing 

In December, AusCann announced the successful manufacture, testing and release of a commercial batch of cannabinoid-based capsules.

Today, AusCann announced it had achieved the same milestone with a low-dose presentation of the capsules. This confirms AusCann's ability to customise cannabinoid dosing for its capsules which is critical for individualised patient treatment.

The company is on-target and progressing towards its goal of having its hard-shell capsules commercially available for doctors to prescribe during the first half of 2020. 

Controlled dose formulations

The Therapeutic Goods Administration's guidance suggests that the general principle for medicinal cannabis dosing should be "start low, go slow". According to the company, it is therefore imperative to provide doctors and their patients with controlled dose formulations in different doses to allow for personalised treatment.

AusCann's ability to customise dosing while ensuring that each capsule is true to label and produced on a commercial scale will assist in providing it with a competitive advantage. 

AusCann CEO Ido Kanyon said, "Auscann has set out to develop cannabinoid-based, controlled-dose capsules patients need to enable accurate dose titration in a convenient formulation for patients and healthcare professionals. Our ability to customise dosing in an accurate and scalable way will enable doctors to personalise dosing. Providing true to label customised dosing and enabling customisable treatment of the patient is what differentiates our product in the market."

Clinical evidence and market expansion

AusCann's capsules provide a medical solution that offers regulated doses in conformance with pharmaceutical quality conformance and regulatory requirements.

Reliable, stable, and standardised medicines are critical to generating quality clinical evidence for cannabinoid-based medicines. This evidence is a prerequisite to market expansion and medical acceptance by healthcare professionals. 

AusCann intends to make its capsules commercially available for prescription to patients in Australia in the first half of 2020 through the Therapeutic Goods Administration's special access scheme and authorised prescriber scheme.

Kanyon said, "we are committed, upon receiving physician and patient feedback from our clinical evaluation, to improving and setting the standard in health outcomes."

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »